NASDAQ:PYXS

Pyxis Oncology Q4 2025 Earnings Results & Report

Pyxis Oncology logo
$1.44 +0.03 (+2.13%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.53%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pyxis Oncology beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 23, 2026. The company reported EPS of -$0.29 versus the -$0.35 consensus estimate, while revenue of $11.04 million topped the $125 thousand estimate by $10.91 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Pyxis Oncology EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.35
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Pyxis Oncology Revenue Results

Actual Revenue
$11.04 million
Expected Revenue
$125 thousand
Beat/Miss
Beat by +$10.91 million
YoY Revenue Growth
N/A

Pyxis Oncology Q4 2025 Earnings FAQ

Pyxis Oncology (NASDAQ:PYXS) reported earnings of -$0.29 per share for Q4 2025, beating the consensus estimate of -$0.35. The report was announced on Monday, March 23, 2026.

Pyxis Oncology reported revenue of $11.04 million for Q4 2025, against a consensus estimate of $125 thousand.

Pyxis Oncology Earnings Headlines

Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $7.00
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS) is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue.

The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.

Founded in 2019 and based in Boston, Massachusetts, Pyxis Oncology was co-founded by Lara Sullivan, who has served as its president and chief executive officer. The company is focused on developing its therapies and does not have marketed products.

View Pyxis Oncology Profile